Loading
A phase 3 trial of Gemcitabine in pancreatic ductal adenocarcinoma, run by GC Cell Corporation, now recruiting.
Safety and Efficacy of Immuncell-LC With Gemcitabine in Resectable Pancreatic Cancer is a phase 3 interventional study registered as NCT04969731 by GC Cell Corporation, with 408 participants planned, started 2021-09-07 and due to reach its primary completion in 2026-12. Interventions recorded: Immuncell-LC, Gemcitabine. Conditions listed: Pancreatic Ductal Adenocarcinoma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Resectable pancreatic ductal adenocarcinoma, Gemcitabine, Cytotoxic chemotherapy.
Shares Resectable pancreatic ductal adenocarcinoma, Gemcitabine, Cytotoxic chemotherapy.
Shares Resectable pancreatic ductal adenocarcinoma, Gemcitabine, Pancreatic ductal adenocarcinoma, Cytotoxic chemotherapy.
Shares Resectable pancreatic ductal adenocarcinoma, Gemcitabine, Cytotoxic chemotherapy.
Shares Resectable pancreatic ductal adenocarcinoma, Gemcitabine, Cytotoxic chemotherapy.
Shares Resectable pancreatic ductal adenocarcinoma, Gemcitabine, Pancreatic ductal adenocarcinoma.
Shares Resectable pancreatic ductal adenocarcinoma, Gemcitabine, Cytotoxic chemotherapy.
Shares Resectable pancreatic ductal adenocarcinoma, Gemcitabine, Pancreatic ductal adenocarcinoma, Cytotoxic chemotherapy.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/